ANI Pharmaceuticals (ANIP) is a US-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of
.8B, trading at $77.97 on the NASDAQ. This SniperIQ fundamentals page covers ANI Pharmaceuticals's valuation (P/E 19.0x, P/B 2.9x), profitability (net margin 9.7%), revenue ($883M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Market Cap
.8B
P/E (TTM)19.0x
Net Margin9.7%
Revenue (FY25)$883M
Full research coverage
8-Quarter Revenue & Margin Trend
Debt Maturity & Coverage
Peer Valuation Comparison
Free Cash Flow & Owner Earnings
AI Signal + Institutional Flow
DCF Valuation Model
Frequently Asked Questions
What is ANI Pharmaceuticals's market cap?
ANI Pharmaceuticals (ANIP) has a market capitalization of approximately
.8B, trading at $77.97 on the NASDAQ. Market cap moves with the live share price.
What is ANI Pharmaceuticals's P/E ratio?
ANI Pharmaceuticals's trailing twelve-month P/E ratio is 19.0x, with a price-to-book (P/B) of 2.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is ANI Pharmaceuticals?
ANI Pharmaceuticals runs a net profit margin of 9.7%, a gross margin of 65.9%, and an operating margin of 13.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does ANI Pharmaceuticals generate?
ANI Pharmaceuticals reported revenue of $883M for fiscal year 2025, with net income of $78M and earnings per share (EPS) of 3.5. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does ANI Pharmaceuticals pay a dividend?
ANI Pharmaceuticals does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is ANI Pharmaceuticals financially healthy?
ANI Pharmaceuticals carries a debt-to-equity ratio of 0.58x and a current ratio of 3.12x, with a market beta of 0.43. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is ANI Pharmaceuticals a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For ANI Pharmaceuticals (ANIP) the key facts are: market cap
.8B, P/E 19.0x, revenue $883M, 52-week range 62.61-99.5. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track ANI Pharmaceuticals's full fundamentals live
Get ANI Pharmaceuticals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.